Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2008

Conditions
Cocaine DependenceOpioid Dependence
Interventions
DRUG

levetiracetam

The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period

Trial Locations (1)

06516

VA CT Healthcare System, West Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT00593125 - Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients. | Biotech Hunter | Biotech Hunter